Preferred Language
Articles
/
jbcd-2525
Bacteriological Findings within Internal Implant Hole Following Flapless Implant Placement
...Show More Authors

Back ground: Microbial penetration inside the implant's internal hole creates a bacterial reservoir that is related with an area of inflamed connective tissue opposite the fixture-abutment junction and this can affect the health of the peri-implant tissue. Aims of the study: Evaluate the types aerobic and anaerobic bacterial count-percentage and difference between Aerobic and Anaerobic microflora in the implant screw hole three months after implant placement. Monitor the periodontal health status of all patients, throughout the study. Material and methods: Study methodology; Eight partially edentulous patients received 20 dental implants and these implants done with flapless surgical procedure. All patients examined clinically to determined their oral health status by examination of their plaque index, Gingival index and Bleeding on probing, each two weeks for 90 days (8visits) throughout the study period. Three months after that, the plaque sample collected from the internal hole of fixture and transfer to bacterial investigation and assessment the amount of anaerobic and aerobic bacteria. Results: Although the anaerobic viable count is higher than that of aerobic, but with statistically not significant difference between those counts (P>0.05). Keywords: screw hole, flapless surgical implant placement, bacterial count, Aerobic and Anaerobic bacteria

Crossref
View Publication Preview PDF
Quick Preview PDF
Publication Date
Sat Oct 03 2020
Journal Name
International Journal Of Diabetes In Developing Countries
The efficacy of once-daily liraglutide as an add-on to oral antidiabetic agents on weight reduction and glycemic control in obese patients with inadequately controlled type 2 diabetes: a retrospective analysis in relation to liraglutide dose escalation within a 7-month treatment period
...Show More Authors

Background This study aimed to evaluate the efficacy of once-daily liraglutide as an add-on to oral antidiabetics (OADs) on glycemic control and body weight in obese patients with inadequately controlled type 2 diabetes (T2D). Methods A total of 27 obese T2D patients who received 7 months (0.6 mg/day for the first month, 1.2 mg/day for 3 months, and 1.8 mg/day for 3 months) of liraglutide treatment as an add-on to OADs were included. Data on body weight (kg), fasting plasma glucose (FPG, mg/dL), postprandial glucose (PPG, mg/dL), and HbA1c (%), were recorded. Results Liraglutide doses of 1.2 mg/day and 1.8 mg/day were associated with significant decreases in body weight (by 8.0% and 11.9%, respectively, p < 0.01 for each) and HbA1c (by 20.0

... Show More
Preview PDF